Nutra Pharma Corp.

(Public, OTC:NPHC)

Step aside Morphine, the new king of chronic pain treatment has entered the building. With Nutra Pharma’s stock rising nearly 2300% year-to-date, its time we see what all the commotion is about. StocksHaven Investments takes a closer look at Nutra Pharma Corp., which believes will begin generating significant revenues within the next 12 months. The company has recently made waves throughout the biotech space with their recent “Best New Product” award winning drug, Cobroxin. The product is the first clinically proven treatment for stage 2 (moderate to severe) chronic pain, and was awarded the honour at the Efficient Collaborative Retail Marketing (ECRM) Conference in Miami, Florida. Winning this was no easy task, as a handful of well known companies attended the conference. The

Nutra Pharma Corp.

(Public, OTC:NPHC)

StocksHaven Investments has confirmed they are set to profile Nutra Pharma Corp. in the coming days, and states that they have also touched base with with Investor Relations in regards to scheduling a tentative conference call with the Chairman and CEO, Rik J Deitsch. Nutra Pharma has recently made waves within the biotech space with their recent “Best New Product” award winning drug, Cobroxin. The product is the first clinically proven treatment for stage 2 (moderate to severe) chronic pain, was awarded the honour at the Efficient Collaborative Retail Marketing (ECRM) Conference in Miami, Florida. The company is also developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS).

Over 50 million Americans suffer from ongoing chronic pain, but that’s all about to change. In August, a biotechnology company, Nutra Pharma, shook the pain world when